Stockscreener 앱 받기
13.36
3.40%
-0.465
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Is Intellia Therapeutics (NTLA) Pricing Look Interesting After Strong Year-To-Date Share Gain? - simplywall.st
A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound - Yahoo Finance
Amova Asset Management Americas Inc. Cuts Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
ARK Investment Management LLC Trims Stake in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Jones Trading Upgrades Intellia Therapeutics (NTLA) - Nasdaq
FDA again targets GLP-1 compounders; Intellia to restart heart disease trial - BioPharma Dive
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at JonesTrading - MarketBeat
This Target Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
NTLA Stock Upgrade: Jones Trading Raises Intellia Therapeutics t - GuruFocus
HC Wainwright Has Pessimistic Outlook of NTLA Q1 Earnings - MarketBeat
Brookline Capital Maintains Buy on Intellia Therapeutics Inc (NTLA) March 2026 - Meyka
Intellia (NTLA) CEO John M. Leonard awarded large option and RSU grants - Stock Titan
Intellia (NTLA) EVP receives stock awards and small tax-driven share sale - Stock Titan
Intellia Therapeutics (NTLA) CMO awarded options and RSUs in Form 4 filing - Stock Titan
Intellia Therapeutics (NTLA) CFO granted stock options and RSUs - Stock Titan
Intellia Therapeutics (NTLA) CSO awarded options and RSUs - Stock Titan
Intellia Therapeutics (NTLA) EVP gets stock awards and sells shares for taxes - Stock Titan
Intellia Therapeutics (NTLA) CAO awarded 17,250 restricted stock units - Stock Titan
Intellia Therapeutics (NASDAQ:NTLA) Given New $48.00 Price Target at Canaccord Genuity Group - MarketBeat
FDA’s lifting of clinical holds sends Intellia upwards - The Pharma Letter
Intellia Therapeutics (NTLA) Highlights Promising Findings in He - GuruFocus
NTLA: Leerink Partners Raises Price Target and Maintains Outperf - GuruFocus
Leerink Partners Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
NTLA: RBC Capital Raises Price Target to $15, Maintains Sector P - GuruFocus
Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial - Sahm
Royal Bank Of Canada Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
Wells Fargo Raises Price Target for Intellia Therapeutics (NTLA) to $15 | NTLA Stock News - GuruFocus
Wells Fargo & Company Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
Intellia Therapeutics (NTLA) Highlights Promising Findings in Hereditary Angioedema Treatment - GuruFocus
Citizens Jmp Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
HC Wainwright Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $30.00 - MarketBeat
Vanguard Group Inc. Acquires 192,651 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Chardan Raises Price Target on Intellia Therapeutics to $27 From $26, Keeps Buy Rating - marketscreener.com
NTLA Sees Price Target Raised by Citizens, Rating Maintained | N - GuruFocus
RBC Raises Price Target on Intellia Therapeutics to $15 From $9, Keeps Sector Perform, Speculative Risk - marketscreener.com
Intellia presents data on experimental gene therapy for hereditary angioedema - Investing.com India
NTLA: HC Wainwright & Co. Raises Price Target to $30.00 | NTLA S - GuruFocus
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 - Stock Titan
Demystifying Intellia Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Intellia Therapeutics, Inc. $NTLA is Contrarius Group Holdings Ltd's 6th Largest Position - MarketBeat
BofA Maintains NTLA Neutral for Intellia Therapeutics on Mar 2, 2026 - Meyka
Chardan Capital Raises Price Target for NTLA, Maintains Buy Rati - GuruFocus
Intellia Therapeutics (NTLA) files ATM to sell up to $400M of stock via Jefferies - Stock Titan
Oppenheimer reiterates Intellia stock rating on clinical hold resolution - Investing.com
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 10.7% on Analyst Upgrade - MarketBeat
Intellia Therapeutics Shares Surge Amid Steller Earnings and Promising CRISPR Advances - StocksToTrade
Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Outperform at William Blair - MarketBeat
William Blair Upgrades Intellia Therapeutics to Outperform From Market Perform - marketscreener.com
US FDA lifts clinical hold on Intellia’s heart disease gene therapy trial - WTVB
Intellia Resumes Key Trial and Expands ATM Program - TipRanks
Intellia Therapeutics Says US FDA Removes Clinical Hold on Magnitude Phase 3 Trial for Nexiguran Ziclumeran - marketscreener.com
Intellia Therapeutics Inc increases at-the-market offering program to $1.04 billionSEC filing - marketscreener.com
Intellia Therapeutics IncIncreases At-The-Market Offering Program To $1.04 Billion- SEC Filing - TradingView
Intellia Therapeutics Expands ATM Program to $1.04 Billion Under Amended Jefferies Agreement - TradingView
FDA Lifts Hold on Intellia Therapeutics' (NTLA) Phase 3 Trial - GuruFocus
FDA clears Intellia (Nasdaq: NTLA) MAGNITUDE trial; ATM capacity raised - Stock Titan
Intellia: FDA Removes Clinical Hold On IND For MAGNITUDE Phase 3 Trial Of Nexiguran Ziclumeran - Nasdaq
Intellia Therapeutics announces FDA lift of clinical hold on Magnitude phase 3 clinical trial in ATTR-CM - marketscreener.com
Intellia gets FDA nod to resume second gene therapy trial after safety pause - Reuters
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - Yahoo Finance
Why Intellia Therapeutics (NTLA) Is Up 9.0% After FDA Lifts MAGNITUDE-2 Hold And EPS Beat - Sahm
Intellia Advances Gene Editing Programs Toward Hereditary Angioedema Commercial Reality - Yahoo Finance
Intellia Trial Milestones Refocus Attention On Gene Editing Risk And Reward - Sahm
Intellia Therapeutics Q4 Loss Of US$0.83 EPS Tests Long Term Bullish Narratives - Sahm
Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory - Yahoo Finance
Intellia Therapeutics Eyes 2026 Pivotal CRISPR Milestone - The Globe and Mail
Intellia Therapeutics (NTLA) Announces Fiscal Q4 and Full Year 2025 Financial Results - Insider Monkey
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline - Finviz
Intellia Therapeutics (NASDAQ:NTLA) Given "Buy" Rating at Chardan Capital - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2025 Earnings Call Transcript - Insider Monkey
Wedbush Raises Price Target on Intellia Therapeutics to $12 From $7, Keeps Neutral Rating - marketscreener.com
Intellia Therapeutics Inc (NTLA) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Intellia Therapeutics Inc (NTLA) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Unveiling an 87% Potential Upside in Gene Editing Innovation - DirectorsTalk Interviews
3.87%
자본화:
|
볼륨(24시간):